CRISPR Therapeutics AG — Director's Dealing 2017

Aug 2, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2017-08-01

Reporting Person: Ho Tony W (See Remarks)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-08-01	Restricted Stock Units	$	A	75000	Acquired		Common Shares (75000)	Direct
2017-08-01	Stock Options (Right to Buy)	$16.90	A	260000	Acquired	2027-08-01	Common Shares (260000)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F2: The restricted stock units vest in two equal annual installments on 8/1/2018 and 8/1/2019.

F3: This option was granted on August 1, 2017 with respect to 260,000 Common Shares of which 25% shall vest on 8/1/2018 and the remaining 75% shall vest in 36 equal monthly installments on the final day of each succeeding calendar month.